Why the study?
In patients with severe AS and a small aortic annulus, TAVR might offer better hemodynamics and lower PPM risk than sAVR, but risks like coronary obstruction and annulus rupture must be managed.
Answers are grounded in this paper and cite their sources.
Demonstrates the feasibility of using the Acurate Neo 2 self-expanding transcatheter heart valve in patients with a very small native aortic annulus.
Transcatheter aortic valve replacement (TAVR) is a treatment of choice in patients with symptomatic severe aortic valve stenosis (AS) and intermediate-to-high surgical risk. The presence of a small aortic annulus (SAA) has been associated with a higher incidence of prosthesis-patient mismatch (PPM) when surgical aortic valve replacement (sAVR) is performed. TAVR might be a treatment option offering better hemodynamics with a lower incidence of PPM. When a severe AS with a SAA is treated, TAVR-related risk as the coronary obstruction and the annulus rupture, must be also prevented. We present a case of a TAVR in a very small aortic annulus; to our knowledge, this is the smallest native aortic annulus treated percutaneously in a tricuspid stenotic aortic valve with a Self-Expanding Transcatheter Heart Valve (THV) Acurate Neo 2.
No takes yet. Share an insight, caveat, or question.
Medda et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: